Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE
Conditions
Interventions
20vPnC
20vPnC
+2 more
Locations
21
United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Kaiser Permanente Sacramento
Sacramento, California, United States
Kaiser Permanente South Sacramento
Sacramento, California, United States
Kaiser Permanente San Jose
San Jose, California, United States
Kaiser Permanente Santa Clara
Santa Clara, California, United States
Accel Research Sites - Clinical Research Unit
DeLand, Florida, United States
Start Date
February 14, 2019
Primary Completion Date
October 9, 2019
Completion Date
October 9, 2019
Last Updated
November 23, 2020
NCT07205289
NCT06731374
NCT06044077
NCT06790290
NCT05569954
NCT07019909
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions